Financing ·
Lenders extend forbearance period for Karyopharm's debt obligations to Oct. 22
KPTIKaryopharm Therapeutics Inc.
Karyopharm Therapeutics has entered into an amendment extending the forbearance period under its Forbearance Agreement and Limited Waiver to Indentures. The extension pushes the end date from October 15, 2026, to October 22, 2026. This temporary relief provides additional time for the company to address covenant compliance or negotiate a permanent resolution with lenders. Karyopharm Therapeutics operates in the biotechnology industry, focusing on the discovery and development of therapies targeting nuclear export.